Serving the Society Since 1986
Advanced Search
Volume 39 Issue 5
October 2024
    Citation: Kangyin Li, Qi Liu, Yan Wu, Bihao Wu, Shaohong Chen, Xinghai Zhang, Xiaoying Jia, Rui Gong, Yucai Peng, Huajun Zhang, Sandra Chiu. A bivalent Delta/BA.5 mRNA vaccine elicits broad immune responses against various lineages of SARS-CoV-2 including JN.1 .VIROLOGICA SINICA, 2024, 39(5) : 833-835.  http://dx.doi.org/10.1016/j.virs.2024.08.003
    shu

    A bivalent Delta/BA.5 mRNA vaccine elicits broad immune responses against various lineages of SARS-CoV-2 including JN.1

    cstr: 32224.14.j.virs.2024.08.003

    • a. Key Laboratory of Virology and Biosafety, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, 430062, China;

    • b. University of Chinese Academy of Sciences, Beijing, 100049, China;

    • c. Liverna Therapeutics Inc., Zhuhai, 519000, China;

    • d. Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230027, China;

    • e. Department of Laboratory Medicine, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230027, China;

    • f. Key Laboratory of Anhui Province for Emerging and Reemerging Infectious Diseases, Hefei, 230027, China

    • Highlights
      1. A bivalent Delta/BA.5 mRNA vaccine provides protection against BA.5 in K18-ACE2 mice.
      2. The vaccine protects hamsters from both Delta and BA.5 infections.
      3. The animal immune sera neutralizes various lineages of variants including JN.1.
    • 加载中

    • Electronic Supplementary Material

      10.1016j.virs.2024.08.003-ESM.docx

      1. Chalkias, S., Eder, F., Essink, B., Khetan, S., Nestorova, B., Feng, J., Chen, X., Chang, Y., Zhou, H., Montefiori, D. et al., 2022. Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial. Nat. Med. 28, 2388-2397.

      2. Feikin, D. R., Higdon, M. M., Abu-Raddad, L. J., Andrews, N., Araos, R., Goldberg, Y., Groome, M. J., Huppert, A., O'Brien, K. L., Smith, P. G. et al., 2022. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet. 399, 924-944.

      3. Li J, Liu Q, Liu J, Fang Z, Luo L, Li S, Lei Y, Li Z, Jin J, Xie R, Peng Y., 2022. Development of bivalent mRNA vaccines against SARS-CoV-2 variants. Vaccines (Basel). 10, 1807.

      4. Roemer, C., Sheward, D. J., Hisner, R., Gueli, F., Sakaguchi, H., Frohberg, N., Schoenmakers, J., Sato, K., O'Toole, A., Rambaut, A. et al., 2023. SARS-CoV-2 evolution in the Omicron era. Nat Microbiol. 8, 1952-1959.

      5. Shuai, H., Chan, J. F., Hu, B., Chai, Y., Yuen, T. T., Yin, F., Huang, X., Yoon, C., Hu, J. C., Liu, H. et al., 2022. Attenuated replication and pathogenicity of SARS-CoV-2 b.1.1.529 Omicron. Nature. 603, 693-699.

      6. Ssentongo, P., Ssentongo, A. E., Voleti, N., Groff, D., Sun, A., Ba, D. M., Nunez, J., Parent, L. J., Chinchilli, V. M., Paules, C. I., 2022. SARS-CoV-2 vaccine effectiveness against infection, symptomatic and severe COVID-19: a systematic review and meta-analysis. BMC Infect Dis. 22, 439.

      7. Tegally, H., Moir, M., Everatt, J., Giovanetti, M., Scheepers, C., Wilkinson, E., Subramoney, K., Makatini, Z., Moyo, S., Amoako, D. G. et al., 2022. Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa. Nat. Med. 28, 1785-1790.

      8. Ukwishaka, J., Ndayishimiye, Y., Destine, E., Danwang, C., Kirakoya-Samadoulougou, F., 2023. Global prevalence of coronavirus disease 2019 reinfection: a systematic review and meta-analysis. BMC Public Health. 23, 778.

      9. Uraki, R., Kiso, M., Iwatsuki-Horimoto, K., Yamayoshi, S., Ito, M., Chiba, S., Sakai-Tagawa, Y., Imai, M., Kashima, Y., Koga, M. et al., 2023. Characterization of a SARS-CoV-2 EG.5.1 clinical isolate in vitro and in vivo. Cell Rep. 42, 113580.

      10. Wu, Y., Shen, Y., Wu, N., Zhang, X., Chen, S., Yang, C., Zhou, J., Wu, Y., Chen, D., Wang, L. et al., 2022. Omicron-specific mRNA vaccine elicits potent immune responses in mice, hamsters, and nonhuman primates. Cell Res. 32, 949-952.

      11. Zhang, X., Chen, S., Cao, Z., Yao, Y., Yu, J., Zhou, J., Gao, G., He, P., Dong, Z., Zhong, J., et al., 2022. Increased pathogenicity and aerosol transmission for one SARS-CoV-2 B.1.617.2 Delta variant over the wild-type strain in hamsters. Virol. Sin. 37, 796-803.

    • 加载中

    Figures(1)

    PDF

    Article Metrics

    Article views(5654) PDF downloads(16) Cited by()

    Related
    Proportional views

      A bivalent Delta/BA.5 mRNA vaccine elicits broad immune responses against various lineages of SARS-CoV-2 including JN.1

        Corresponding author: Yucai Peng, pengyucai@live-rna.com
        Corresponding author: Huajun Zhang, hjzhang@wh.iov.cn
        Corresponding author: Sandra Chiu, qiux@ustc.edu.cn
      • a. Key Laboratory of Virology and Biosafety, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, 430062, China;
      • b. University of Chinese Academy of Sciences, Beijing, 100049, China;
      • c. Liverna Therapeutics Inc., Zhuhai, 519000, China;
      • d. Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230027, China;
      • e. Department of Laboratory Medicine, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230027, China;
      • f. Key Laboratory of Anhui Province for Emerging and Reemerging Infectious Diseases, Hefei, 230027, China
      • Received Date: 25 October 2023
      • Accepted Date: 06 August 2024

      Abstract: Highlights
      1. A bivalent Delta/BA.5 mRNA vaccine provides protection against BA.5 in K18-ACE2 mice.
      2. The vaccine protects hamsters from both Delta and BA.5 infections.
      3. The animal immune sera neutralizes various lineages of variants including JN.1.

        HTML

      Figure (1)  Reference (11) Relative (20)

      目录

      This journal is a member of, and subscribes to the principles of, the Committee on Publication Ethics (COPE)

      鄂ICP备05001977号

         

      鄂公网安备 42010602003674号

      Copyright © 2019 Virologica Sinica. All rights reserved

      /

      DownLoad:  Full-Size Img  PowerPoint
      Return
      Return